Logo

SBCWW

SBC Medical Group Holdings Incorporated

SBCWW

SBC Medical Group Holdings Incorporated • NASDAQ
$0.14 ▲ 19.66% (+0.02)
Market Cap $14.43 M
52w High $0.17
52w Low $0.14
Dividend Yield 0%
P/E 0
Volume 3.14K
Outstanding Shares 103.04M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $43.353M ▼ $14.02M ▼ $12.825M ▲ 29.582% ▲ $0.12 ▲ $19.27M ▲
Q2-2025 $43.359M ▼ $15.456M ▲ $2.458M ▼ 5.67% ▼ $0.024 ▼ $14.226M ▼
Q1-2025 $47.329M ▲ $13.531M ▼ $21.502M ▲ 45.432% ▲ $0.21 ▲ $32.086M ▲
Q4-2024 $44.421M ▼ $29.155M ▼ $6.539M ▲ 14.721% ▲ $0.064 ▲ $7.003M ▼
Q3-2024 $53.085M $29.404M $2.833M 5.337% $0.03 $14.132M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $127.431M ▼ $321.363M ▲ $73.304M ▲ $247.988M ▲
Q2-2025 $152.741M ▲ $315.299M ▲ $70.647M ▲ $244.592M ▲
Q1-2025 $132.056M ▲ $284.606M ▲ $58.283M ▼ $226.446M ▲
Q4-2024 $125.044M ▼ $266.083M ▼ $71.061M ▼ $195.109M ▼
Q3-2024 $137.393M $296.479M $90.958M $204.981M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $12.825M ▲ $-20.884M ▼ $-12.158M ▼ $11.568M ▲ $-25.31M ▼ $-21.061M ▼
Q2-2025 $2.458M ▼ $-8.34M ▼ $16.377M ▲ $7.182M ▲ $20.685M ▲ $-8.851M ▼
Q1-2025 $21.502M ▲ $1.929M ▲ $-978.807K ▲ $-280.38K ▼ $7.012M ▲ $1.174M ▲
Q4-2024 $6.548M ▲ $-7.303M ▼ $-4.548M ▲ $11.381M ▲ $-12.349M ▼ $-7.894M ▼
Q3-2024 $2.833M $42.812M $-8.814M $-1.181M $136.008M $39.994M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been rising steadily over the past few years, and profits have grown faster than sales. The company has moved from relatively modest earnings to clearly profitable operations, with improving efficiency in how it turns sales into operating and net income. Operating profit has been stable to slightly higher recently, while cash-style earnings (like EBITDA) dipped a bit in the latest year but remain comfortably positive. Overall, the income statement shows a small but growing consulting and medical services group that is scaling up without sacrificing profitability.

Balance Sheet

Balance Sheet The balance sheet looks conservative and steadily stronger. Total assets have grown, with cash building up noticeably, giving the company a solid liquidity cushion. Debt is very low and has even ticked down, while shareholders’ equity has climbed strongly, suggesting profits are being retained and the financial base is thickening. In simple terms, the company appears lightly leveraged, more self-funded, and progressively more robust from a capital standpoint.

Cash Flow

Cash Flow Cash generation from day‑to‑day operations has become consistently positive and has improved over time, which supports the quality of reported profits. After an earlier period of investment that led to negative free cash flow, the company has now settled into a pattern of positive free cash flow, even after modest spending on capital needs. This indicates that the business is not only profitable on paper but also bringing in real cash, with some flexibility to reinvest, strengthen the balance sheet, or pursue strategic moves.

Competitive Edge

Competitive Edge SBC has built a strong position in Japan’s aesthetic and broader medical services market through a well-known core brand and a pioneering franchise model. Its advantage comes from a large network of clinics, high name recognition, and a loyal customer base that returns for repeat treatments. The company supports franchisees with marketing, training, procurement, and clinic setup, which can make its platform attractive to doctors and operators. Scale allows better purchasing terms, and the portfolio now spans multiple medical areas, reducing dependence on any single niche. Together, this creates a meaningful competitive moat in its home market, though expansion abroad introduces new competitive dynamics and execution risk.

Innovation and R&D

Innovation and R&D Innovation here is more about business model and digital tools than pure medical technology. SBC was early in using a franchise approach in this industry and has layered on a multi-brand strategy to target different patient segments and price points. It is investing in IT systems for customer management, remote consultations, and loyalty programs, plus tools like a custom translation app to serve foreign patients and support medical tourism. Automation is used behind the scenes to streamline admin work. On the R&D side, the company is leaning on acquisitions and partnerships, such as the planned tie-up with a research-focused firm to deepen capabilities in areas like hair restoration, orthopedics, and proprietary skincare. This suggests a gradual shift from being mainly a service operator to also owning more of the underlying products and know‑how.

Summary

SBC Medical Group Holdings is a relatively young listed company that has shown steady growth in sales, clear improvement in profitability, and strengthening cash generation. Its balance sheet is cash-rich and lightly indebted, which gives it room to pursue expansion. The core business benefits from strong branding, a first-mover franchise system, and a diversified service mix within aesthetic and related medical fields. At the same time, the company is pushing into digital tools, new clinic concepts, and international markets, and is starting to build more in-house R&D through acquisitions. Key things to watch going forward include how well it executes global expansion, integrates new businesses, and maintains service quality and margins while it scales up beyond its home base.